YOU MAKE THE DIFFERENCE

Thanks to your support, 2017 was a tremendous year for the Leukemia & Lymphoma Society of Canada. Your generosity is responsible for the advances we have made in understanding and treating blood cancers and moreover, improving quality of life for all Canadians affected by blood cancers.

You help fund research to find the next breakthrough therapy; you provide information and support to patients, and you make sure patients have access to lifesaving treatments.

Extraordinary progress is bringing us closer to cures. You make that possible.

With Gratitude,

Alicia Talarico
President

Ted Moroz
Chair of the Board
KNOWLEDGE IS POWER

We are here to let the 138,100 Canadians living with blood cancers, their families, caregivers, and healthcare professionals know that they are not alone. LLSC provides information, education and support services, at no cost, to all members of the blood cancer community.

With over 137 types of blood cancers and related disorders, patients often struggle to navigate the complex cancer landscape. We are here to support patients every step of the way: from diagnosis to recovery and beyond. Research will help us achieve an end to blood cancers. In the meantime, it is our mission to improve quality of life for blood cancer patients and their families.

LLSC is the only voluntary organization dedicated to supporting patients with all blood cancers in Canada.
As there are no means of preventing blood cancers, our research agenda is focused on finding treatments and cures. Thanks to recent advances in blood cancer research, the treatment landscape is evolving with new options for blood cancer patients.

The introduction of Chimeric antigen receptor T cell therapy (CAR-T) has ushered in the new era of immunotherapy in cancer treatment.

- Immunotherapy trains and uses the patient’s own immune system to fight cancer
- CAR-T therapy has shown promise in early clinical trials against some hard-to-treat forms of leukemia and lymphoma

After more than four decades of little progress in treating acute myeloid leukemia (AML) 2017 saw Vyxeos™.

- innovative combination of two standard chemotherapies to treat patients with two high-risk types of AML
- the drugs are combined into a single infusion to deliver a more optimal ratio of the drugs with less toxicity

We celebrate these achievements, but for every victory in blood cancers, challenges remain. That is why we remain steadfast in our commitment: advancing the most promising research to improve and save the lives of patients.
PATIENTS HELPING PATIENTS

For months, 38-year-old Jennifer Marley didn’t know what was causing her neck and back pain. In 2003, doctors diagnosed her with acute myeloid leukemia. Suddenly, Jennifer faced difficult questions the medical professionals couldn’t answer: how should she tell her kids, then five and seven, that she was sick? What would she say to her friends? What did other cancer patients have to say about chemotherapy?

For seven months, Jennifer’s life revolved around treatment. After four rounds of chemotherapy and a bone marrow transplant, Jennifer went into remission. Despite the ordeal, Jennifer believes that “... many positive things that came out of this experience. It’s allowed me to better understand the importance of family and friends, and to live life every day.”

Now, she feels it is her turn to help others coping with a blood cancer diagnosis by participating in the First Connection Program. “I like being a First Connection Volunteer. It is a way that I can support others and hopefully help a tiny little bit on making their journey with leukemia easier.”

She also serves on her local Light The Night Volunteer Leadership Committee, and last year her team Sklar Wilton & Associates/Logic Group Staff & Friends, 65 members strong, raised $29,100. Through her ongoing participation and support of LLSC, Jennifer is bringing hope and help to other Canadians affected by blood cancers.

“Life is a gift. I’m now on bonus time. I had the type of cancer that a lot of people don’t survive. I did. So what can I do now to not only live life and enjoy it every day, but to give back, help others, and make a difference”

– Jennifer Marley

68% of Canadians would FEEL HELPLESS faced with a blood cancer diagnosis

>27,000 PATIENTS have connected with LLSC

190 Peer to Peer MATCHES
Donors are the lifeblood of LLSC. In UFCW Canada, we have a partner that embodies the essence of philanthropy. We are privileged and humbled to have worked alongside this committed and dynamic collective for more than 32 years.

In 1985, UFCW Canada members made a commitment to support the LLSC. Their dedication has cumulatively raised $36 million to advance understanding of blood cancers, seek cures, improve treatments and reach patients. They are shining example of charitable giving in communities across the country.

“Each year, UFCW Canada and LLSC together provide support and hope to people living with blood cancers. We renew our partnership each year because our members can feel the tangible impact of donor dollars at work. Our ongoing efforts to fund research mean that today, kids and adults with blood cancers are living longer,” explains Paul Meinema, President of UFCW Canada.

In 2017, UFCW Canada members raised over $2.5 million for the blood cancer community, making them, once again, LLSC’s single largest source of support.

Thank You members of UFCW Canada!
STRENGTH IN NUMBERS

LLSC volunteers continue to make a significant impact in the blood cancer community, selflessly dedicating their time, talent and passion. Our volunteers are changing the landscape for blood cancer patients in Canada. Instrumental in everything we do, our volunteers are everywhere.

Mission
 Volunteers work directly with blood cancer patients and caregivers offering hope, help and support

Community
 Over five signature events, volunteers run, hike, walk, and build teams that unite blood cancer communities across the country

Leadership
 We are grateful for the unwavering support of top business and scientific leaders in helping fulfill our mission

12.5K
12,500 mission VOLUNTEERS

35K
35,000 community VOLUNTEERS

135
135 leadership VOLUNTEERS
We believe that the most efficient way to finding cures for blood cancers is by directing as much funding as possible to the best and most promising research, while providing patients with the information, education and services they need to successfully navigate the blood cancer landscape.

LLSC receives no government or cancer society funding. We are incredibly grateful for the tremendous generosity of our supporters, who make everything we do possible. LLSC is committed to the highest standards of transparency and accountability. Your support is invested wisely.

In 2017, we invested more than $7.4 million in the creation of programs and delivery of services to improve the lives of Canadians affected by blood cancers from coast to coast, including:

- $4.1 million in innovative, life-changing research to accelerate treatments, therapies and cures
- $3.3 million towards funding patient services, programs and education

To access audited financial statements, please visit http://www.llscanada.org/who-we-are/financials
OUR MISSION

Cure blood cancers and improve the quality of life of patients and their families.

NATIONAL LEADERS

Ted Moroz  
Chair of the Board

Scott Carroll  
Vice Chair

Eli Gembom  
Treasurer

Dr. Keith Humphries  
Secretary & Chair of Medical & Scientific Committee

DIRECTORS

Dr. Louis J. DeGennaro

Alex Beraskow

Anouk Collet

Rick Lancaster

Marie Lapointe

Gord McFarlane

Paul R. Meinema

Kathleen Meriwether

Paul Petrelli

Dr. Aaron D. Schimmer
Contact Us

The Leukemia & Lymphoma Society of Canada
2 Lansing Square, Suite 804, Toronto, ON M2J 4P8  1-877-668-8326